Analysis on Medication Regularity and Action Mechanism of Tibetan Medicine in Treatment of Chronic Atrophic Gastritis Based on Data Mining and Net-Work Pharmacology
Objective To study the mechanism of action of Tibetan medicine in the treatment of chronic atrophic gastritis(CAG).Method Retrieve Tibetan medicine prescriptions for the treatment of CAG on CNKI,Wanfang Database,and VIP Journal Database.Ex-tract information from literature that meets the inclusion and exclusion criteria,construct a database for high-frequency Tibetan medicine statistics,conduct correlation analysis,and obtain core drugs for Tibetan medicine treatment of CAG.Retrieve the active ingredients and targets of Tibetan medicine in the TCMSP database,use GeneCads and OMIM online databases to obtain disease targets,conduct Wayne analysis on drug action targets and disease-related targets,and determine potential targets for Tibetan medicine treatment of CAG.Use String database and Cytoscape 3.7.1 software to construct a"drug compound potential target"interaction network and protein interaction(PPI)network diagram.Conduct GO function and KEGG pathway enrichment analysis on key targets using the DAVID database.Results A total of 78 Tibetan medicine prescriptions were included,including 136 Tibetan medicines.Based on confidence and correlation,four core drugs including Terminalia chebula,Cardamom,Piper longum,Pomegranate,and 32 active ingredients including quercetin,luteolin,rosacetin,ellagic acid,piperine,and dehydrodiisoeugenol were selected.92 core targets including AKT1,TNF,IL6,TP53,MMP9,HIF1A,CASP3,BCL2,IL1B,PTGS2,and 747 GO entries were obtained.KEGG enrichment entries involved 139 pathways,including cancer related pathways,lipid and atherosclerosis,and AGE-RAGE.Conclusion Four Tibetan medicines,including cardamom,piper longum,pomegranate,and chebula,were selected through data mining as core drugs for the treatment of CAG.Network pharmacology methods were used to analyze and conclude that these four Tibetan medicines may inhibit the release of inflammatory cytokines by down-regulating the expression of genes such as AKT1,TNF,IL6,and TP53.It also plays a role in the treatment of CAG by regulating cancer-related pathways,lipid and atherosclerosis,AGE-RAGE,fluid shear stress and atherosclerosis,IL-17 and other signaling pathways,which directly or indirectly participate in the anti-inflammatory,antioxidant,and vascular regeneration processes of the body.
data mining technologynetwork pharmacologyTibetan medicinechronic atrophic gastritis
国家科技期刊平台
NSTL
万方数据
